Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
ApexOnco Front Page
Recent articles
The company might have blown Enliven out of the water.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
The company will try to get the Komzifti QTc prolongation warning removed.
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
The company’s AN9025 will shortly enter phase 1.
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
